|
1）Hinson SR, Pittock SJ, Lucchinetti CF, et al. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology. 2007; 69: 2221-31
|
|
|
|
2）Misu T, K Fujihara, Kakita A, et al. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain. 2007; 130: 1224-34
|
|
|
|
|
|
3）Cortese I, Chaudhry V, So YT, et al. Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2011; 76: 294-300
|
|
|
|
|
|
4）Weinshenker BG. Plasma exchange for severe attacks of inflammatory demyelinating diseases of the central nervous system. J Clin Apheresis. 2001; 16: 39-42
|
|
|
|
|
|
5）三須建郎，藤原一男，糸山泰人．Brain and Nerve. 2008; 60: 527-37
|
|
|
|
|
6）Bermel RA, Rudick RA. Interferon-beta treatment for multiple sclerosis. Neurotherapeutics. 2007; 4: 633-46
|
|
|
|
|
|
7）Goodin DS, Ebers G, Traboulsee A, et al. The interferon beta-1b 16-year long-term follow-up study: clinical outcomes. Ann Neurol. 2006; 60: S35
|
|
|
|
|
|
8）Kappos L, Radue E, OʼConnor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010; 362: 387-401
|
|
|
|
|
|
9）Cohen J, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010; 362: 402-15
|
|
|
|
|
|
10）Polman C, OʼConnor P, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006; 354: 899-910
|
|
|
|
|
|
11）Bozic C, Richman S, Plavina T, et al. Anti-John Cunningham virus antibody prevalence in multiple sclerosis patients. Ann Neurol. 2011; 70: 742-50
|
|
|
|
|
|
12）Goodin DS, Arnason BG, Coyle PK, et al. The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2003; 61: 1332-8
|
|
|
|
|
|
13）OʼConnor P, Wolinsky J, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011; 365: 1293-303
|
|
|
|
|
|
14）Muraro PA, Bielekova B. Emerging therapies for multiple sclerosis. Neurotherapeutics. 2007; 4: 676-92
|
|
|
|
|
|
15）Lutterotti A, Martin R. Getting specific: monoclonal antibodies in multiple sclerosis. Lancet Neurol. 2008; 7: 538-47
|
|
|
|
|
|
16）Nakamura M, Nakazawa T, Doi H, et al. Early high-dose intravenous methylprednisolone is effective in preserving retinal nerve fiber layer thickness in patients with neuromyelitis optica. Graefes Arch Clin Exp Ophthalmol. 2010; 248: 1777-85
|
|
|
|
|
|
17）Yoshida H, Ando A, Sho K, et al. Anti-aquaporin-4 antibody-positive optic neuritis treated with double-filtration plasmapheresis. J Ocul Pharmacol Ther. 2010; 26: 381-5
|
|
|
|
|
|
18）Keegan M, Pineda AA, McClelland RL, et al. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology. 2002; 58: 143-6
|
|
|
|
|
|
19）Watanabe S, Nakashima I, Misu T, et al. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler. 2007; 13: 128-32
|
|
|
|
|
|
20）Miyamoto K, Kusunoki S. Intermittent plasmapheresis prevents recurrence in neuromyelitis optica. Ther Apher Dial. 2009; 13: 505-8
|
|
|
|
|
21）Watanabe S, Misu T, Miyazawa I, et al. Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Mult Scler. 2007; 13: 968-74
|
|
|
|
|
|
22）Jarius S, Aboul-Enein F, Waters P, et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain. 2008; 131: 3072-80
|
|
|
|
|
|
23）Mok CC, To CH, Mak A, et al. Immunoablative cyclophosphamide for refractory lupus-related neuromyelitis optica. J Rheumatol. 2008; 35: 172-4
|
|
|
|
|
|
24）Birnbaum J, Kerr D. Optic neuritis and recurrent myelitis in a woman with systemic lupus erythematosus. Nat Clin Pract Rheumatol. 2008; 4: 381-6
|
|
|
|
|
|
25）Falcini F, Trapani S, Ricci L, et al. Sustained improvement of a girl affected with Devicʼs disease over 2 years of mycophenolate mofetil treatment. Rheumatology (Oxford). 2006; 45: 913-5
|
|
|
|
|
|
26）Jacob A, Matiello M, Weinshenker BG, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol. 2009; 66: 1128-33
|
|
|
|
|
|
27）Weinstock-Guttman B, Ramanathan M, Lincoff N, et al. Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol. 2006; 63: 957-63
|
|
|
|
|
|
28）Cree BA, Lamb S, Morgan K, et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology. 2005; 64: 1270-2
|
|
|
|
|
|
29）Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol. 2008; 65: 1443-8
|
|
|
|
|
|
30）Capobianco M, Malucchi S, di Sapio A, et al. Variable responses to rituximab treatment in neuromyelitis optica (Devicʼs disease). Neurol Sci. 2007; 28: 209-11
|
|
|
|
|
|
31）Kieseier BC, Stüve O, Dehmel T, et al. Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: im-plication for cellular immune responses. JAMA Neurol. 2013; 70: 390-3
|
|
|
|
|
|
32）Ayzenberg I, Kleiter I, Schröder A, et al. Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol. 2013; 70: 394-7
|
|
|
|
|
|
33）Araki M, Aranami T, Matsuoka T, et al. Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab. Mod Rheumatol. 2013; 23: 827-31
|
|
|
|
|
|
34）Pittock SJ, Lennon VA, McKeon A, et al. Eculizumab in AQP4-IgG-positive relapsing neuro-myelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol. 2013; 12: 554-62
|
|
|
|
|
|
35）越智博文，吉良潤一．免疫性神経疾患に関する調査研究班平成19年度班会議抄録集．2008. p.52-3
|
|
|
|
|
|
36）Shimizu Y, Yokoyama K, Misu T, et al. Development of extensive brain lesions following interferon beta therapy in relapsing neuromyelitis optica and longitudinally extensive myelitis. J Neurol. 2008; 255: 305-7
|
|
|
|
|
|
37）Warabi Y, Matsumoto Y, Hayashi H. Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination. J Neurol Sci. 2007; 252: 57-61
|
|
|
|
|